Login / Signup

BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity.

Zsófia Agnes BittnerXiao LiuMaria Mateo TortolaAna Tapia-AbellánSangeetha ShankarLiudmila AndreevaMatthew S J ManganMarianne Rebecca SpalingerHubert KalbacherPeter DuewellMarta LovottiKarlotta BoschSabine DickhöferAna MarcuStefan StevanovicFranziska HersterYamel Cardona GloriaTzu-Hsuan ChangFrancesca BorkCarsten L GreveMarkus W LöfflerOlaf-Oliver WolzNadine A SchillingJasmin Beate Kuemmerle-DeschnerSamuel WagnerAnita DelorBodo GrimbacherOliver HantschelMichael ScharlHao WuEicke LatzAlexander N R Weber
Published in: The Journal of experimental medicine (2021)
Activity of the NLRP3 inflammasome, a critical mediator of inflammation, is controlled by accessory proteins, posttranslational modifications, cellular localization, and oligomerization. How these factors relate is unclear. We show that a well-established drug target, Bruton's tyrosine kinase (BTK), affects several levels of NLRP3 regulation. BTK directly interacts with NLRP3 in immune cells and phosphorylates four conserved tyrosine residues upon inflammasome activation, in vitro and in vivo. Furthermore, BTK promotes NLRP3 relocalization, oligomerization, ASC polymerization, and full inflammasome assembly, probably by charge neutralization, upon modification of a polybasic linker known to direct NLRP3 Golgi association and inflammasome nucleation. As NLRP3 tyrosine modification by BTK also positively regulates IL-1β release, we propose BTK as a multifunctional positive regulator of NLRP3 regulation and BTK phosphorylation of NLRP3 as a novel and therapeutically tractable step in the control of inflammation.
Keyphrases
  • nlrp inflammasome
  • tyrosine kinase
  • epidermal growth factor receptor
  • oxidative stress
  • transcription factor
  • drug delivery
  • cancer therapy